Wockhardt Limited · NSE:WOCKPHARMA

Wockhardt — Investor Presentation (July 2006)

29 slides from Wockhardt's investor presentation, July 2006

  1. Slide 1: Wockhardt Limited

    Slide 1: Wockhardt Limited

    Wockhardt Limited Ui “7 WOCKHARDT

  2. Slide 2: Overview

    Slide 2: Overview

    Overview • Leading Indian Pharmaceutical and Biotechnology major – Comprehensive all round capabilities from “Concept to Market” • Only Pharmaceutical Company in India to be selected as Business Super Brand – Awarded by The Superbrands Council –internationally reputed organisation spread over 45 cou

  3. Slide 3: Overview

    Slide 3: Overview

    Overview • Globally Diversified Entity – US & Europe contribute to more than 50% of revenues – Successful acquisition track-record • Three acquisitions in Europe • 3500 Wockhardians across locations in India & abroad – Over 500 Wockhardians overseas

  4. Slide 4: Overview

    Slide 4: Overview

    Overview ƒ Sales $ 324mn ƒ Op. Margins 23 % ƒ PAT $ 57mn ƒ ROCE 28 % ƒ RONW 32 % ƒ R&D Spend @ 8 % of annual turnover ƒ Market Cap $ 1.3 billion

  5. Slide 5: Ten year Snapshot

    Slide 5: Ten year Snapshot

    Ten year Snapshot • Sales performance – CAGR of 21% over 10 years • Profitability – CAGR of 22% over 10 years • R&D spend – CAGR of 28% over 10 years • IPO Investor rewarded – 27% annualized returns

  6. Slide 6: Geographical Revenue Split

    Slide 6: Geographical Revenue Split

    Geographical Revenue Split ROW 11% India 37% Europe 41% USA 11% Increasing International focus US & EU Business Constitutes more than 50% of total revenues

  7. Slide 7: Wockhardt Advantage

    Slide 7: Wockhardt Advantage

    Wockhardt Advantage R&D & Manufacturing Competitiveness Biopharmaceuticals & Generics Regulated India ROW Markets

  8. Slide 8: Manufacturing Capabilities

    Slide 8: Manufacturing Capabilities

    Manufacturing Capabilities • Strategically located manufacturing facilities in UK & India • Approved by major regulatory authorities including US FDA Steriles Vials, Ampoules, Cartridges, lyophilized products, Cephalosporins Biotech API’s: 3 major expression systems: yeast, e-coli, mammalian cell Fo

  9. Slide 9: Research & Development

    Slide 9: Research & Development

    Research & Development

  10. Slide 10: R&D - Model

    Slide 10: R&D - Model

    R&D - Model Biotech New Chemical Research & Development Generics Entity

  11. Slide 11: R&D - Highlights

    Slide 11: R&D - Highlights

    R&D - Highlights Multi - disciplinary R&D Skilled Team IPR Creation Recombinant 400 Scientists 150 patents biopharmaceuticals filed 100 PhD’s Generics Includes 3 biotech patents New Chemical Entity

  12. Slide 12: Biopharmaceuticals – Value Chain

    Slide 12: Biopharmaceuticals – Value Chain

    Biopharmaceuticals – Value Chain IE S I T ABIL C AP SBU established KET -Already marketing to 7 R countries MA - Expected to market to 19 TO countries by 2006 Registrations P T - 26 Registrations received CE - 55+ registrations in the Business O N pipeline C - To be followed by registrations in EU &

  13. Slide 13: Biopharmaceuticals – Development

    Slide 13: Biopharmaceuticals – Development

    Biopharmaceuticals – Development 2004 2005 2006 -Wepox -Wepox -Wepox -Wosulin -Wosulin -Wosulin -Biovac B -Biovac B -Biovac B -Wosulin cartridges -Wosulin cartridges & pens & pens -Interferon Alpha 2B -Glargine Capabilities to develop and launch one biopharmaceutical product each year

  14. Slide 14: Generics

    Slide 14: Generics

    Generics • Vertically integrated model – 35 DMF filings • Filings in 3 strategic areas – Injectables (Cephalosporins & Non-Cephalosporins) – Blockbuster molecules going off-patent – Value Added Generics (NDDS, Niche, follow-on Para IV) • 20+ ANDAs pending approval • 50+ products in various stages of

  15. Slide 15: New Chemical Entity

    Slide 15: New Chemical Entity

    New Chemical Entity NCE Pipeline Preclinical Clinical NCE Indication Form Early Preclin. Adv. Preclin. Phase I Phase II MRSA, WCK 771 resistant IV infections Respiratory WCK 1152 Oral infections IV MRSA, WCK 2370 resistant Oral infections Gram +ve Oral WCK 2664 MRSA,VRE, VISA resist. IV Skin Topical

  16. Slide 16: International Business

    Slide 16: International Business

    KAMERICA TRALIA. EANI/ a Grrockuaror

  17. Slide 17: International Business

    Slide 17: International Business

    International Business • International business is a key growth driver for Wockhardt – CAGR of 45% over last 10 years • 52% of International business is from Europe & US International Business as % of sales 80% 63% 60% 40% 20% 20% 10% 0% 1994 1999 2005

  18. Slide 18: International Business

    Slide 18: International Business

    International Business Footprints across major pharmaceutical markets • Europe – Wockhardt UK Limited – Esparma GmbH • USA – Wockhardt USA Inc. • ROW Countries – Biopharmaceuticals

  19. Slide 19: Europe

    Slide 19: Europe

    Europe Wockhardt UK Ltd. – Largest Indian generic company – 2nd largest in the hospital business – Amongst top 10 generic companies – US FDA approved comprehensive manufacturing capabilities Esparma GmbH • Innovatively structured acquisition in Germany in 2004 – Entry in the largest European Generic

  20. Slide 20: USA

    Slide 20: USA

    USA • Own sales and marketing organization in the US since 2004 – 12 products being marketed • 20+ ANDA’s pending approval US business to grow 50%+ in medium term

  21. Slide 21: ROW

    Slide 21: ROW

    ROW • Launch of Biopharmaceuticals in various ROW markets initiated – Three pronged marketing and distribution strategy Sales & Mktg Strategic Joint Distribution Organization Ventures Partnerships • Sales & marketing set up in major markets of erstwhile CIS, S E Asia, Latin America and North Africa

  22. Slide 22: International Business – Growth Drivers

    Slide 22: International Business – Growth Drivers

    International Business – Growth Drivers Front-end Infrastructure in place in major markets • Germany:esparma GmbH Europe • UK: Wockhardt UK Ltd International • Wockhardt US Inc. US Business • Aggressive ANDA programme • Biotech park commissioned ROW • Registrations in place • Marketing infrastructur

  23. Slide 23: Indian Business

    Slide 23: Indian Business

    Indian Business

  24. Slide 24: Indian Business - Overview

    Slide 24: Indian Business - Overview

    Indian Business - Overview • 5 therapy focused marketing divisions – 1200 field personnel catering to 1,50,000 doctors • Strong Focus and Superior Product Mix – Covers 47% of the therapeutic segments – 6 brands Rank amongst the Top 300 of the Industry • Young Portfolio – Products launched <5 years c

  25. Slide 25: Indian Business - Overview

    Slide 25: Indian Business - Overview

    Indian Business - Overview Creating Niche thru. Biotech & NDDS Products Biotech Diabetology • Growth of 54% in ‘05 • Wockhardt’s diabetology portfolio grew by 58% in 2005 • 3 successful products in market • Pioneer in Novel Delivery - EPO: Market Leader Systems for Oral Anti-Diabetic - rhu Insulin:

  26. Slide 26: Indian Business - Diabetology Portfolio

    Slide 26: Indian Business - Diabetology Portfolio

    Indian Business - Diabetology Portfolio 2006 COMPLETE DIABETOLOGY OFFERING ,Glargine 2005 Wosulin Cartridges Wosulin Cartridges & Pens & Pens 2003 - 2004 Insulin - vials Insulin - vials Insulin - vials - Wosulin R - Wosulin R - Wosulin R - Wosulin 50/50 - Wosulin 50/50 - Wosulin 50/50 - Wosulin30/70

  27. Slide 27: www.wockhardtdiabetic.com

    Slide 27: www.wockhardtdiabetic.com

    www.wockhardtdiabetic.com A dedicated website for diabetics www.wockhardtdiabetic.com

  28. Slide 28: Indian Business - Growth Drivers

    Slide 28: Indian Business - Growth Drivers

    Indian Business - Growth Drivers • Will continue to outperform the industry growth rate • Biotech, Diabetology and Nephrology would continue to remain the key growth drivers • New strategic group focusing on Specialty Nutrition created • Focus on Power brands

  29. Slide 29: Thank You

    Slide 29: Thank You

    Y Thank You Grrockuaror

Source: Internet Archive copy of wockhardt.com

More decks from Wockhardt Limited

All 22 Wockhardt decks